There was significant interest in galectin-3 as a biomarker when it was first implicated in HF in 2004, when it was found to be specifically overexpressed in the myocardium of Ren-2 rats that would go on to develop HF [140]. This evidence concerns the gene LGALS3 and hydrops fetalis.